pCPA Monthly Trends & Insights – January 2018

pCPA Monthly Trends & Insights – January 2018

The January 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are:

• Two new drug products have initiated pCPA negotiations, for a total of 36 active negotiations;
• Four negotiations have been completed/closed, for a total of 200 joint completed/closed negotiations; and
• No new drug products were added to the “No pCPA Negotiations” list, for a total of 57 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level.

Negotiation Initiation

• Two new drug products have initiated pCPA negotiations since the last update, for a total of 36 active negotiations

*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
** Note: This is the second negotiation for Victoza, the first was closed in January 2014.

Signals Decoded:

The rapid initiation of negotiations for Spinraza (1 month vs. 2017 median of 5+ months) appears to signal that this file is a priority for pCPA. It is also interesting to note that the CDEC recommendation included the collection of real-world evidence as a condition of reimbursement, highlighting the need for ongoing monitoring of patient information after public reimbursement.

Negotiations Completed

• Four negotiations have been completed/closed since the last update, for a total of 200 joint completed/closed negotiations.
  • Three negotiations were completed:

• • One negotiation was closed (in September 2017):

Signals Decoded:

The Strensiq file is the latest example of a negotiation that was successfully completed after the initial negotiation efforts failed to result in an agreement.

No pCPA Negotiation

• No new drug products were added to the “No pCPA Negotiations” list, for a total of 57 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level

In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. Based on information collected by MORSE Consulting, the latest update since January 31, 2017 is:

• Eight new drug products received a CDEC or pERC recommendation or notification to implement since the last update, for a total of approximately 27 products under pCPA Consideration.

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.